Fish oil and red yeast rice studied for lowering blood cholesterol

A great deal of scientific evidence shows that cholesterol-reducing medications known as statins can help prevent coronary artery disease. Although the safety of these medications has been well documented, as many as 40 percent of patients who receive a prescription for statins take the drug for less than one year.

Doctors believe that several factors -- including cost, adverse effects, poor understanding of statin benefits and patients' reluctance to take prescription medications long term -- may explain why some patients stop taking these medicines.

In the July issue of Mayo Clinic Proceedings, a group of researchers from Pennsylvania examine whether an alternative approach to treating high blood cholesterol may provide an effective treatment option for patients who are unable or unwilling to take statins.

Researchers followed 74 patients with high blood cholesterol who met standard criteria for using statin therapy. Patients were randomly assigned to either the alternative treatment group or the statin group and followed for three months.

The alternative treatment group participants received daily fish oil and red yeast rice supplements, and they were enrolled in a 12-week multidisciplinary lifestyle program that involved weekly 3.5-hour educational meetings led by a cardiologist, dietitian, exercise physiologist and several alternative or relaxation practitioners. Red yeast rice is the product of yeast grown on rice. A dietary staple in some Asian countries, it contains several compounds known to inhibit cholesterol production.

The statin group participants received 40 milligrams (mg) of Zocor (simvastatin) daily, as well as printed materials about diet and exercise recommendations. At the end of the three-month period, participants from both groups underwent blood cholesterol testing to determine the percentage change in LDL cholesterol.

The researchers noted that there was a reduction in LDL cholesterol levels in both groups. The alternative treatment group experienced a 42.4 percent reduction, and the statin group experienced a 39.6 percent reduction. Members of the alternative therapy group also had a substantial reduction in triglycerides, another form of fat found in the blood, and lost more weight.

"Our study was designed to test a comprehensive and holistic approach to lipid lowering," notes the study's lead author, David Becker, M.D., a Chestnut Hill Hospital and University of Pennsylvania Health System cardiologist. "These results are intriguing and show a potential benefit of an alternative, or naturopathic, approach to a common medical condition."

Dr. Becker acknowledges that a larger, multicenter trial with longer follow-up is necessary to determine long-term compliance with the alternative regimen, because previous studies involving diet and exercise have found a high rate of patients unable or unwilling to follow lifestyle recommendations.

"The excellent adherence in the alternative group was undoubtedly related to the intensive follow-up, education and support provided for this group," says Dr. Becker.

Source: Mayo Clinic

Related stories:

Major discovery in the treatment of aortic valve stenosis
A team of scientists from the Université de Montréal and the Montreal Heart Institute Research Centre, led by Dr. Jean-Claude Tardif, has completed an important study that show how a new type of medication can lead to an improvement in the aortic valve narrowing.
New strategy to cut heart attack risk is effective in initial test
The first clinical trial of a new kind of drug to cut the risk of cardiovascular disease has been found safe and effective at dropping levels of “bad” low density lipoprotein (LDL) cholesterol by as much as 40 percent. High LDL levels increase the risk for heart attack and stroke.
No evidence that widely prescribed statins protect against prostate cancer
A large community-based study refutes previous findings that statins – a top-selling drug class, worldwide -- might cut one’s risk of developing prostate cancer by reducing production of the male hormones that fuel cancer growth.
Nanotechnology's miniature answers to developing world's biggest problems
In a study by the University of Toronto Joint Centre for Bioethics, a panel of international experts ranks the 10 nanotechnology applications in development worldwide with the greatest potential to aid the poor. With a high degree of unanimity, the 63 panelists selected energy production, conversion and storage, along with creation of alternative fuels, as the area where nanotechnology applications are most likely to benefit developing countries.
Chemists move closer toward developing safer, fully-synthetic form of heparin
Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions.
Physical therapists offer low-cost solution to high-cost expenditures for acute low back pain
The American Physical Therapy Association (APTA) concurs with findings from a recent study published in Spine (Volume 33, Number 16) demonstrating that active physical therapy for patients with acute low back pain is associated with better clinical outcomes, decreased use of prescription medications, MRI and epidural injections, and lower healthcare costs than passive physical therapy.
Researchers to begin study aimed at helping Latino HIV patients
Researchers at Wake Forest University Baptist Medical Center will soon begin researching how a lack of trust in formal medicine is contributing to disproportionately higher mortality rates in Latino HIV patients than in white HIV patients across the country.
PSA screening may be biased against obese men, leading to more aggressive cancers
Testing men for elevated levels of prostate-specific antigen (PSA) in the blood -- the gold standard screening test for prostate cancer -- may be biased against obese men, whose PSA levels tend to be deceptively low. And this bias may be creating more aggressive cancers in this population by delaying diagnosis, according to a new study led by investigators in the Duke Prostate Center and the Durham Veterans Affairs (VA) Medical Center.

News discussion:

Medicine & Health news